The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
of concern threatens the efficacy of existing vaccines and therapeutic antibodies and …

Prophylactic and therapeutic drugs are urgently needed to combat coronavirus disease
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

SARS-CoV-2 infection or vaccination produces neutralizing antibody responses that
contribute to better clinical outcomes. The receptor binding domain (RBD) and the N …

Monoclonal antibodies against the SARS-CoV-2 spike protein, notably, those developed by
Regeneron Pharmaceuticals and Eli Lilly and Company have proven to provide protection …

Many SARS-CoV-2 neutralizing antibodies (nAbs) lose potency against variants of concern.
In this study, we developed 2 strategies to produce mutation-resistant antibodies. First, a …

The changing landscape of SARS-CoV-2 Spike protein is linked to the emergence of
variants, immune-escape and reduced efficacy of the existing repertoire of anti-viral …

Abstract COVID-19 pathogen SARS-CoV-2 has infected hundreds of millions and caused
over 5 million deaths to date. Although multiple vaccines are available, breakthrough …

One of the major breakthroughs to combat the current Coronavirus Disease 2019 (COVID-
19) pandemic has been the development of highly effective vaccines against the Severe …

The ongoing Coronavirus Disease 2019 (COVID-19) pandemic caused by Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) threatens global public health and …

A wide range of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
neutralizing monoclonal antibodies (mAbs) have been reported, most of which target the …